TAG Advocacy Brief: Overcoming Barriers to Adopting the Four-Month Regimen

17 July 2026

Drug-sensitive TB treatment can be shortened from six to four months by replacing rifampicin with rifapentine and ethambutol with moxifloxacin. For people with TB, shortening the time on treatment by a third means less time away from work or school, a faster return to life without TB, and fewer healthcare visits and lower out-of-pocket costs along the way. The World Health Organization endorsed the four-month “HPMZ” (isoniazid, rifapentine, moxifloxacin, pyrazinamide) regimen in 2021, but its use remains limited.

Treatment Action Group (TAG) released an advocacy brief reviewing barriers to the adoption of the four-month regimen and how they might be addressed, and offering a narrative framework communities can use to advocate for the regimen in Global Fund Grant Cycle 8 and beyond.

Access the advocacy brief here.

Source: Treatment Action Group